Fate Therapeutics IncFATE

Fate Therapeutics’ most recent quarterly filing reads like a study in contrasts: revenue of $1.3 million for the three months ending March 31, 2026, versus a net loss of $31.2 million, an operating loss of $33.0 million, and a burn rate that gobbled $30.8 million in operating cash. All of that red ink sits atop $284.9 million in assets, with $179.7 million of equity and $135.3 million parked in short-term investments; in other words, the company is solvent but not yet commercial. The $1.3 million figure is itself a reminder of how thin the revenue needle still is: $5 million of it was a clinical development milestone from Ono Pharmaceutical, booked as revenue and deferred over the period in which Ono performed preclinical services. The rest is effectively zero. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1434316/000119312526220696/fate-20260331.htm)

What Fate actually does is develop first-in-class cellular immunotherapies using an induced pluripotent stem cell platform to create off-the-shelf NK and CAR T-cell therapies. The science is serious: FT819, an autologous CAR T-cell therapy for hematologic malignancies, is being tested in clinical trials and has been highlighted in Nature Medicine for rapid B-cell depletion and clinical remission in lupus patients. Fate’s pipeline includes multiple programs for cancer and autoimmune diseases, and the company’s iPSC platform is positioned as the engine for an “off-the-shelf immunotherapy revolution.” The promise is enormous, the peer-reviewed data are promising, and the patient brochures are polished. Yet the commercial engine remains in neutral. (source: FT819 pipeline page, https://www.fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft819/)

The filing also lays out how the company’s cash is deployed. Research and development expense clocked in at $24.7 million for the quarter, while capex was a trifling $239,000-good news for the landlord, less so for anyone waiting for a factory to start churning out vials. Diluted EPS came in at minus $0.26 on 120 million diluted shares, and the company’s cash and equivalents stood at $39.6 million against $30.8 million of operating outflows. The balance sheet still looks healthy relative to the burn, but the runway is finite. Short-term investments of $135.3 million provide some cushion, while the deferred revenue from Ono’s $5 million prepayment sits on the liability side until services are delivered. The optics are neat; the mechanics are less so. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1434316/000119312526220696/fate-20260331.htm)

The company’s ownership filings show that institutional holders can shift without fanfare: the July 8 Schedule 13G/A update reminds investors that dilution remains an ever-present option if the burn continues. The stock is not a ticker; it is a story that trades on hope, science, and the patience of shareholders. Until the first commercial shipment leaves the delivery yard, every bull case is a faith-based instrument. The filing route for deeper facts is SEC EDGAR’s company facts JSON, which aggregates all XBRL disclosures for CIK 0001434316. (source: SEC EDGAR companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001434316.json)

For context on the clinical pipeline and patient recruitment, Fate’s patient-facing pages and clinical trials index provide the human side of the story: the company is actively recruiting patients for CAR T-cell trials in autoimmune diseases and certain cancers. The brochures are informative, the contact email is clinicaltrials@fatetherapeutics.com, and the ambition is clear. What isn’t clear is when the first vial will be invoiced. (source: Clinical Trials index, https://www.fatetherapeutics.com/patients/clinical-trials/)